NCT01356381View on ClinicalTrials.gov

Study to Assess the Effect of 24 Weeks of Treatment With Vildagliptin in Patients With Type 2 Diabetes

PHASE4CompletedINTERVENTIONAL
Enrollment

43

Participants

Timeline

Start Date

April 30, 2011

Primary Completion Date

August 31, 2013

Study Completion Date

August 31, 2013

Conditions
Type 2 Diabetes Mellitus
Interventions
DRUG

Vildagliptin

Dosage 50mg b.i.d.

DRUG

Placebo

50mg bid

Trial Locations (1)

NE4 5PL

Novartis Investigative Site, Newcastle upon Tyne

Sponsors
All Listed Sponsors
lead

Novartis Pharmaceuticals

INDUSTRY